7MW4811 / Mabwell (Shanghai) Biosci - LARVOL DELTA

Mabwell Reveals Encouraging Pre-clinical Data of 7MW4811 at the 15th World ADC Conference (PRNewswire) - "Mabwell...showcased the 'Preclinical Development of 7MW4811, an Mtoxin (MF6)-based Antibody-drug Conjugate for the Treatment of Solid Tumors" as a poster presentation at the 15th World ADC San Diego, held from Nov. 4 to 7, 2024. The post revealed compelling data from the studies on the efficacy of 7MW4811 in treating solid tumors.7MW4811 is developed with Mabwell's next-generation ADC technology (IDDC) platform, and has demonstrated encouraging anti-tumor effects across a range of solid tumors, including lung, colorectal, pancreatic and gastric cancers. Notably, it has shown promising therapeutic potentials in gastrointestinal tumors."

Preclinical • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Pancreatic Cancer